Atherosclerotic Cardiovascular Disease Risk in the HAART-Treated HIV-1 Population

REFERENCES

• American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart As-sociation; 2003.
   Google Scholar
• Kannel WB. Bishop lecture. Contribution of the Framingham Study to preventive cardiology. J Am Coll CardioL 1990;15:206–211.
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cho-lesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041–1046.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Educa-tion Program Adult Treatment Panel III guidelines. Circu-lation. 2004;110:227–239.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resis-tance in human disease. Diabetes. 1988;37:1595–1607.
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002288: 2709–2716.
   Google Scholar
• Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–291.
   PubMed Web of Science ®Google Scholar
• Balkau B, Charles MA, Drivsholm T, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syn-drome. Diabetes Metab. 2002;28:364–376.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Associa-tion. Circulation. 2003;107:499–511.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circu-lation. 2003;107:363–369.
   PubMed Web of Science ®Google Scholar
• Kretowski A, Kinalska I. Serum levels of interleukin-18-a potential marker of cardiovascular death-could be de-termined by genetic predisposition. Circulation. 2003;107:e206-207; author reply e206–207.
   Web of Science ®Google Scholar
• Baldus S, Heeschen C, Meinertz T, et al. Myelopero-xidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipopro-tein-associated phospholipase A2, high-sensitivity C-re-active protein, and risk for incident coronary heart dis-ease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circu-lation. 2004;109:837–842.
   PubMed Web of Science ®Google Scholar
• Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predic-tor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148–1155.
   PubMed Web of Science ®Google Scholar
• Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predic-tors of cardiovascular disease in women. Circulation. 2002;106:1930–1937.
   PubMed Web of Science ®Google Scholar
• Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measur-ing plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999;19:1368–1377.
   PubMed Web of Science ®Google Scholar
• O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Col-laborative Research Group. N Engl J Med. 1999;340:14–22.
   PubMed Web of Science ®Google Scholar
• Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low-to intermediate-risk adults. Circulation. 2003;107:2571–2576.
   PubMed Web of Science ®Google Scholar
• Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an Inter-national AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002;31:257–275.
   PubMed Web of Science ®Google Scholar
• Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med. 2004;55:303–317.
   PubMed Web of Science ®Google Scholar
• Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medi-cal Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–627.
   PubMed Web of Science ®Google Scholar
• Volberding PA, Murphy RL, Barbaro G, et al. The Pavia consensus statement. AIDS. 2003;17\(suppl 1):S170–179.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453–1460.
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Athero-sclerosis Prevention Study. JAMA. 1998;279:1615–1622.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Choles-terol and Recurrent Events trial. Circulation. 1998;97:1446–1452.
   PubMed Web of Science ®Google Scholar
• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (VVOS CO P S). Circulation. 1998;97:1440–1445.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–1357.
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Grover SA, Dorais M, Coupel L. Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol. Epidemiology. 2003;14:315–320.
   PubMed Web of Science ®Google Scholar
• Jensen G, Schnohr P, Faergeman 0, Meinertz H, Nyboe J, Hansen AT. HDL-cholesterol and ischaemic cardiovascu-lar disease in the Copenhagen city heart study. Dan Med Bull. 1980;27:139–142.
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr, Santamarina-Fojo S. Clinical significance of high-density lipoproteins and the development of athero-sclerosis: focus on the role of the adenosine triphosphate-binding cassette protein Al transporter. Am J CardioL 2003;92:10K–16K.
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and in-flammation. Trends Cardiovasc Med. 2001;11:155–161.
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiin-flammatory properties of high-density lipoprotein distin-guish patients from control subjects better than high-den-sity lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–2756.
   PubMed Web of Science ®Google Scholar
• Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expres-sion of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1450–1455.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Vet-erans Affairs High-Density Lipoprotein Cholesterol Inter-vention Trial Study Group. N Engl J Med. 1999;341:410–418.
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001345: 1583–1592.
   Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–167.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombi-nant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–2300.
   PubMed Web of Science ®Google Scholar
• Rader DJ. Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-den-sity lipoprotein. Curr Atheroscler Rep. 2004;6:398–405.
   PubMedGoogle Scholar
• Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144:S33–42.
   PubMed Web of Science ®Google Scholar
• Austin MA, Hokanson JE,Edwards KL.Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.
   Google Scholar
• Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8–14.
   PubMedGoogle Scholar
• Ford ES, Mokdad AH, Giles WH. Trends in waist circum-ference among U.S. adults. Obes Res. 2003;11:1223–1231.
   PubMedGoogle Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the meta-bolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359.
   PubMed Web of Science ®Google Scholar
• Bruno R, Gazzaruso C, Sacchi P, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr. 2002;31:363–365.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and develop-ment of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–1077.
   PubMed Web of Science ®Google Scholar
• Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care. 2003;26:1251–1257.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive pro-tein, the metabolic syndrome, and risk of incident cardio-vascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391–397.
   PubMed Web of Science ®Google Scholar
• Sattar N, Gaw A, Scherbakova O, et al. Metabolic syn-drome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419.
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Dia-betes Care. 2003;26:575–581.
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, Zinman B, Haffner SM. Identification of subjects with insulin resis-tance and beta-cell dysfunction using alternative defini-tions of the metabolic syndrome. Diabetes. 2003;52:2740–2747.
   PubMed Web of Science ®Google Scholar
• Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108:1546–1551.
   Google Scholar
• Reilly MP, Lqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:3872–3878.
   PubMed Web of Science ®Google Scholar
• Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular dis-ease. Am J Cardiol. 2003;92:3J–9J.
   Google Scholar
• Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lip/dol. 2003;14:561–566.
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33.
   PubMed Web of Science ®Google Scholar
• Banerjee RR, Lazar MA. Resistin: molecular history and prognosis. J Mol Med. 2003;81:218–226.
   PubMed Web of Science ®Google Scholar
• Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 200213: 18–23.
   Google Scholar
• Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and meta-bolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003;17:1503–1511.
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–2476.
   PubMed Web of Science ®Google Scholar
• Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circu-lation. 2001104: 3052–3056.
   Google Scholar
• Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocar-dial infarction in men. JAMA. 2004;291:1730–1737.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002420: 868–874.
   Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Com-parison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565.
   PubMed Web of Science ®Google Scholar
• Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coro-nary artery smooth muscle cells. Circulation. 2003;108:1930–1932.
   PubMed Web of Science ®Google Scholar
• Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogen-esis. Arterioscler Thromb Vasc Biol. 2000;20:2094–2099.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P com-ponent. J Biol Chem. 1997;272:32817–32823.
   PubMed Web of Science ®Google Scholar
• Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sc/ USA. 2002;99:13043–13048.
   PubMed Web of Science ®Google Scholar
• Verma S, Badiwala MV, Weisel RD, et al. C-reactive pro-tein activates the nuclear factor-kappaB signal transduc-tion pathway in saphenous vein endothelial cells: implica-tions for atherosclerosis and restenosis. J Thorac Cardiovasc Surg. 2003;126:1886–1891.
   PubMed Web of Science ®Google Scholar
• Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis. 2003;14:335–340.
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
   Google Scholar
• Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Lmmunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995;45:635–641.
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab. 2003;29:65–71.
   PubMed Web of Science ®Google Scholar
• Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syn-drome: a population-based study. Diabetes Care. 2000;23:1835–1839.
   PubMed Web of Science ®Google Scholar
• Reilly MP, Wolfe ML, Localio AR, Rader DJ. C-reactive protein and coronary artery calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). Arterioscler Thromb Vasc Biol. 2003;23:1851–1856.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study. AIDS. 2003;17:1179–1193.
   PubMed Web of Science ®Google Scholar
• Carr A. Cardiovascular risk factors in HIV-infected pa-tients. J Acquir Immune Defic Syndr. 2003;34\(suppl 1):S73–78.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050–2056.
   PubMed Web of Science ®Google Scholar
• Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coro-nary atherosclerosis and arteriosclerosis in young hu-man-immunodeficiency-virus-positive patients. Coron Artery Dis. 2000;11:41–46.
   PubMed Web of Science ®Google Scholar
• Schecter AD, Berman AB, Yi L, et al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA. 200198: 10142–10147.
   Google Scholar
• Dhawan S, Pun RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-1-tat pro-tein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in hu-man endothelial cells. Blood. 1997;90:1535–1544.
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Buttini M, Limoges J, Bock P, Gendelman HE. An analysis of HIV-1-associated inflammatory prod-ucts in brain tissue of humans and SCID mice with HIV-1 encephalitis. J Neurovirol. 1997;3:401–416.
   PubMed Web of Science ®Google Scholar
• Olivetta E, Percario Z, Fiorucci G, et al. HIV-1 Nef induces the release of inflammatory factors from human mono-cyte/macrophages: involvement of Nef endocytotic sig-nals and NF-kappa B activation. J Immunol. 2003;170:1716–1727.
   PubMed Web of Science ®Google Scholar
• Lala SG, Madhi SA, Pettifor JM. The discriminative value of C-reactive protein levels in distinguishing between community-acquired bacteraemic and respiratory virus-associated lower respiratory tract infections in HIV-1-infected and -uninfected children. Ann Trop Paediatr. 2002;22:271–279.
   PubMed Web of Science ®Google Scholar
• Stahl CP, Wideman CS, Spira TJ, Haff EC, Nixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood. 1993;81:1801–1807.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327:329–337.
   PubMed Web of Science ®Google Scholar
• Sposito AC, Caramelli B, Sartori AM, Ramires JA. The lipoprotein profile in HIV infected patients. Braz J Infect Dis. 1997;1:275–283.
   PubMedGoogle Scholar
• Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003; 289: 2978–2982.
   PubMed Web of Science ®Google Scholar
• Grinspoon S. The pathophysiology of HIV-1 related insu-lin resistance and dyslipidemia. In: Program and ab-stracts of the 10th Conference on Retroviruses and Op-portunistic Infections; February 10–14, 2003; Boston, MA. Abstract 161.
   Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of periph-eral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–58.
   PubMed Web of Science ®Google Scholar
• Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4:411–416.
   PubMed Web of Science ®Google Scholar
• Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS. 200115:2001–2010.
   Google Scholar
• Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Revised March 23,2004. Panel on Clinical Practices for Treatment of HIV Infections. Available at: http://aidsinfo.nih.gov/guidelines/. Ac-cessed September 1,2004.
   Google Scholar
• Hruz PW, Murata H, Qiu H, Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes. 2002;51:937–942.
   PubMed Web of Science ®Google Scholar
• Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concen-trations. AIDS. 2002;16:859–863.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogen-esis of HIV-1-protease inhibitor-associated peripheral li-podystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351:1881–1883.
   PubMed Web of Science ®Google Scholar
• Xu A, Yin S, Wong L, Chan KW, Lam KS. Adiponectin ameliorates dyslipidemia induced by the human immuno-deficiency virus protease inhibitor ritonavir in mice. Endo-crinology. 2004;145:487–494.
   PubMed Web of Science ®Google Scholar
• Hui DY. HIV protease inhibitors and atherosclerosis. J Clin Invest. 2003;111:317–318.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JR. The SREBP pathway: regula-tion of cholesterol metabolism by proteolysis of a mem-brane-bound transcription factor. Cell. 1997;89:331–340.
   PubMed Web of Science ®Google Scholar
• Muller PY, Miserez AR. Identification of mutations in the gene encoding sterol regulatory element binding protein (SREBP)-2 in hypercholesterolaemic subjects. J Med Genet. 2002;39:271–275.
   PubMed Web of Science ®Google Scholar
• Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459–481.
   PubMed Web of Science ®Google Scholar
• Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003;42:81–92.
   PubMed Web of Science ®Google Scholar
• Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterol-regulatory element-binding protein. AIDS. 2002;16:1587–1594.
   PubMed Web of Science ®Google Scholar
• Fajas L, Schoonjans K, Gelman L, et al. Regulation of peroxisome proliferator-activated receptor gamma ex-pression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: impli-cations for adipocyte differentiation and metabolism. Mo/ Cell Biol. 1999;19:5495–5503.
   Web of Science ®Google Scholar
• Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS. 2004;18:137–151.
   PubMed Web of Science ®Google Scholar
• Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry. 2003;42:14711–14719.
   PubMed Web of Science ®Google Scholar
• Blanco F, Garcia-Benayas T, Jose de la Cruz J, Gonzalez-Lahoz J, Soriano V. First-line therapy and mitochondrial damage: different nucleosides, different findings. HIV Clin Trials. 2003;4:11–19.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Ward DJ, Hessenthaler SM, et al. Im-provement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARH EEL study. Clin Infect Dis. 2004;38:263–270.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, et al., Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine ana-logue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is re-flected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr. 200230: 271–277.
   Google Scholar
• Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochon-dria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 2002;29:117–121.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Casula M, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutane-ous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385–393.
   PubMed Web of Science ®Google Scholar
• Nolan D, Hammond E, James 1, McKinnon E, MaIlal S. Contribution of nucleoside-analogue reverse tran-scriptase inhibitor therapy to lipoatrophy from the popu-lation to the cellular level. Anti vir Ther. 2003;8:617–626.
   PubMed Web of Science ®Google Scholar
• Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associ-ated with atherogenic lipoprotein changes and endothe-lial dysfunction. Circulation. 2001;104:257–262.
   PubMed Web of Science ®Google Scholar
• de Gaetano Donati K, Rabagliati R, Tumbarello M, et al. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS. 2003;17:765–768.
   PubMed Web of Science ®Google Scholar
• Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:441–449.
   PubMed Web of Science ®Google Scholar
• George SL, Swindells S, Knudson R, Stapleton JT. Unex-plained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. Am J Med. 1999;107:624–630.
   PubMed Web of Science ®Google Scholar
• Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R, et al. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost. 2004;10:19–25.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–2982.
   PubMed Web of Science ®Google Scholar
• Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396–1405.
   PubMed Web of Science ®Google Scholar
• Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodefi-ciency virus and receiving antiretroviral therapy: recom-mendations of the Adult AIDS Clinical Trial Group Cardio-vascular Disease Focus Group. Clin Infect Dis. 2000;31:1216–1224.
   PubMed Web of Science ®Google Scholar
• Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-re-lated lipid abnormalities. Lancet. 1998;352:1031–1032.
   PubMed Web of Science ®Google Scholar
• Koppel K, Bratt G, Eriksson M, et al. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11:451–455.
   PubMed Web of Science ®Google Scholar
• Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in H IV-infected patients receiving combination therapy: Are dif-ferent antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056–1074.
   Google Scholar
• Squires K, Gatell J, Piliero P, et al. A1424-007: 48-week safety and efficacy results from a phase 11 study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4–8, 2001; Chicago, IL.
   Google Scholar
• Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, ran-domized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week re-sults. AIDS. 2003;17:2603–2614.
   PubMed Web of Science ®Google Scholar
• Murphy R, Thiry A, Mancini M, Pokrovsky V, Rozenbaum W. Switch to atazanavir from nelfinavir associated with cholesterol and triglyceride improvement: 12 wk results from BMS A1424-044 [abstract LbPeB9013]. In: Program and abstracts of the AIDS 2002 XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain.
   Google Scholar
• Cahn P, Pantaleo G, Gatell J, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile. Pre-sented at: XlVth World Congress of Cardiology; May 5–9, 2002; Sydney, Australia.
   Google Scholar
• Haas DW, Zala C, Schrader S, et al. Atazanavir plus saquinavir once daily favorably affects total cholesterol (IC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial A1424-009, week 48) [abstract 42]. Last update 2002. Available at: http://63.126.3.84/2002/Abstract/13797.htm. Ac-cessed February 12, 2003.
   Google Scholar
• Noor M, Grasela D, Parker R, et al. The effect of atazanavir vs lopinavir/ritonavir on insulin-stimulated glu-cose disposal rate in healthy subjects. Presented at the 11th CROI, 2004. Abstract 702.
   Google Scholar
• van Leth F, Phanupak P, Gazzard B, et al. Lipid changes in patients using first-line antiretroviral therapy regimens containing either nevirapine, efavirenz or both, together with stavudine and lamivudine. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunis-tic Infections; February 10–14, 2003; Boston, MA. Ab-stract 752.
   Google Scholar
• Negredo E, Ribalta J, Paredes R, et al. Reversal of athero-genic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383–1389.
   PubMed Web of Science ®Google Scholar
• Fumero E, Fisac C, Crespo M. Metabolic and body com-position changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz, or nevirapine: twelve-month results of a randomized study (LipNEFA). In: Program and abstracts of the XIV Interna-tional AIDS Conference; July 7–12, 2002; Barcelona, Spain.
   Google Scholar
• Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodefi-ciency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab. 2003;88:5186–5192.
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 1999;13:805–810.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
   PubMed Web of Science ®Google Scholar
• Law M, Friis-Moller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003;4:1–10.
   PubMedGoogle Scholar
• The Writing Committee of the D:A:D Study Group. Cardio- and cerebrovascular events in HIV-infected per-sons. AIDS. 2004;18:1811–1817.
   PubMed Web of Science ®Google Scholar
• Klein D, Hurley L, Queensbury C, et al. Hospitalization for coronary heart disease and myocardial infarction among men with HIV-1 infection: follow-up through 12/31/03. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004, San Francisco, CA.
   Google Scholar
• Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702–710.
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocar-dial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486.
   PubMed Web of Science ®Google Scholar
• Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506–512.
   PubMed Web of Science ®Google Scholar
• Holmberg SD, Moorman AC, Williamson JM, et al. Pro-tease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747–1748.
   PubMed Web of Science ®Google Scholar
• Toborek M, Lee YW, Pu H, et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothe-lium. J Neurochem. 2003;84:169–179.
   PubMed Web of Science ®Google Scholar
• Jahoor F, Gazzard B, Phillips G, et al. The acute-phase protein response to human immunodeficiency virus in-fection in human subjects. Am J Physiol. 1999;276: E1092–1098.
   PubMed Web of Science ®Google Scholar
• Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Im-mune Defic Syndr. 2003;32:210–214.
   PubMed Web of Science ®Google Scholar
• Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther. 2003;8:9–15.
   PubMed Web of Science ®Google Scholar
• Henry K, Zackin R, Dube M, Hammer S, Sprecher D, Currier J. ACTG 5056s: metabolic status and cardiovas-cular disease risk for a cohort of HIV-1 infected persons durably suppressed on an indinavir containing regimen (ACTG372A). In: Program and abstracts of the 9th Con-ference on Retroviruses and Opportunistic Infections; February 24–28, 2002; Seattle, WA.
   Google Scholar
• Sklar P, Blackwelder W, Csako G, et al. C-reactive protein may be an important biomarker of cardiovascular risk and does not appear to be confounded by antiretroviral use or HIV viremia. In: Program and abstracts of the 10th Con-ference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 742.
   Google Scholar
• Melchior JC, Niyongabo T, Henzel D, Durack-Bown I, Henri SC, Boulier A. Malnutrition and wasting, immunodepression, and chronic inflammation as inde-pendent predictors of survival in HIV-infected patients. Nutrition. 1999;15:865–869.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129.
   PubMed Web of Science ®Google Scholar
• Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with pro-tease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598.
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recom-mendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222–235.
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230–3236.
   PubMed Web of Science ®Google Scholar
• Kirstein LM, Greenblatt RM, Anastos K, et al. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2002;29:495–503.
   PubMed Web of Science ®Google Scholar
• Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219–1230.
   PubMed Web of Science ®Google Scholar
• Reiss P. New insights in the clinical management of HIV-1 associated metabolic complications - Putting guidelines into practice. In: Program and abstracts of the 10th Con-ference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 163.
   Google Scholar
• Martinez E, Arnaiz J, Podzamczer D, et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Kastelein JJP, Murphy RL, et al, for the Atlantic Study team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407–2414.
   PubMed Web of Science ®Google Scholar
• van Leth F, Andrews S, Grinsztjen B et al. Virologic failure by baseline CD4 count and plasma viral load in patients using nevirapine and /or efavirenz: a 2NN substudy. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA. Abstract 550.
   Google Scholar
• Fisac C, Fumero E, Crespo M, et al. Metabolic changes in patients switching from a protease inhibitor-containing regimen to abacavir, efavirenz or nevirapine: 24-month results of a randomized study. In: Program and abstracts of 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Francisco, CA. Ab-stract 78.
   Google Scholar
• Shahmanesh M, Das S, Stolinski M, et al. Insulin resis-tance and apolipoprotein B kinetics: a comparison of protease inhibitor, efavirenz, or nevirapine-containing antiretroviral regimens. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic In-fections; February 8–11, 2004; San Francisco, CA. Ab-stract 704.
   Google Scholar
• Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:10–14
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Phar-macokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569–577.
   PubMed Web of Science ®Google Scholar
• Benesic A, Zilly M, Kluge F, et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infec-tion and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection. 2004;32:229–233.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Balestre E, Thiebaut R, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med. 2004;5:133–139.
   PubMed Web of Science ®Google Scholar
• Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Read. 2000;10:162–169.
   PubMedGoogle Scholar
• Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lan-cet. 2004;363:429–438.
   PubMed Web of Science ®Google Scholar
• Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292:210–218.
   PubMed Web of Science ®Google Scholar
• Kumar P, Rodriguez-French A, Thompson M, et al. Pospective study of hyperlipidemia in ART-naive subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (E5540002). In: Program and abstracts of the 9th Confer-ence on Retroviruses and Opportunistic Infections; Feb-ruary 24–28, 2002; Seattle, WA. Abstract 33.
   Google Scholar
• Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regi-men therapy (START II). AIDS. 2000;14:1601–1610.
   PubMed Web of Science ®Google Scholar
• Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between indi-vidual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr. 2000;24:310–315.
   PubMed Web of Science ®Google Scholar
• Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and meta-bolic disorders in human immunodeficiency virus-in-fected patients. Clin Infect Dis. 2002;34:649–657.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year random-ized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with pro-tease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700–705.
   PubMed Web of Science ®Google Scholar
• Sanne I, Cahn P, Percival L, et al. Comparative results (phase 11 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naive HIV-positive patients (A1424-008). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chicago, IL. Ab-stract 667.
   Google Scholar
• Segerer S, Bogner JR, Walli R, Loch 0, Goebel FD. Hy-perlipidemia under treatment with proteinase inhibitors. Infection. 1999;27:77–81.
   PubMed Web of Science ®Google Scholar
• Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4:29–36.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 in-fected patients results in an anti-atherogenic lipid profile. AIDS. 2001; 15:2407
   PubMed Web of Science ®Google Scholar
• Tashima K, Morales-Ramirez JO, Butcher D, et al. Ab-dominal CT-scan sub-study of study DPC-006 [abstract 0-13]. In: Program and abstracts of the 3rd European Workshop on Lipodystrophy and Metabolic Disorders (Marbella, Spain). France: Kobe, 2002.
   Google Scholar
• Haubrich R, Miller C, Gathe J, Pearce D, Dretler R, Petersen C. The effect of NFV versus EFV on fasting lipid levels: interim analysis from a prospective randomized study in treatment naive patients (AG1127). In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27–30, 2002; San Diego, CA. Abstract H–1914
   Google Scholar